Drugs / Plasma rich in growth factors
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06115005 | Jun 2022 → Dec 2023 | macular holes | Minia University | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01915979 | Feb 2014 → May 2015 | rotator cuff syndrome | Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias | Completed | No outcome recorded |
| Phase 3 | NCT02039531 | Aug 2011 → Feb 2013 | osteoarthritis, knee | Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT06952998 | Nov 2025 → May 2026 overdue | ulcer of lower limbs | Biotechnology Institute IMASD | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT05595772 Comparator | Feb 2022 → Jul 2023 | — | Minia University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasma rich in growth factors | “Plasma rich in growth factors (PRGF), a subtype of P-PRP (pure platelet-rich plasma), is a supernatant enriched in plasma and platelet-derived morphogens, proteins, and growth factors.” NCT05595772 ↗ |
| Known as | PRGF | “Plasma rich in growth factors (PRGF), a subtype of P-PRP (pure platelet-rich plasma), is a supernatant enriched in plasma and platelet-derived morphogens, proteins, and growth factors.” NCT05595772 ↗3“Topical application of Plasma Rich in Growth Factors (PRGF)” NCT06952998 ↗ “Biological: Plasma rich in growth factors (PRGF)” NCT01915979 ↗ “Plasma rich in growth factors ( PRGF )” NCT06115005 ↗ |
| Modality | Other / unclassified | “PRGF, a subtype of P-PRP (pure platelet-rich plasma)” NCT05595772 ↗ |
| Route | Other | “This group will receive a total of three intraarticular injections of 6-8 ml.” NCT01915979 ↗ |